Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
M.D. Ph.D., 50 Northern Ave, Boston, Massachusetts 02210, Chief Scientific Officer, Executive Vice President, Global Research Vertex Pharmaceuticals Incorporated; Senior Lecturer on Genetics and on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results